A multi-metabolite signature robustly predicts long-term mortality in the PREDIMED trial and several US cohorts.
Fernández-Duval G, Razquin C, Wang F, Yun H, Hu J, Guasch-Ferré M, Rexrode K, Balasubramanian R, García-Gavilán J, Ruiz-Canela M, Clish CB, Corella D, Gómez-Gracia E, Fiol M, Estruch R, Lapetra J, Fitó M, Serra-Majem L, Ros E, Liang L, Dennis C, Asensio EM, Castañer O, Planes FJ, Salas-Salvadó J, Hu FB, Toledo E, Martínez-González MA.
Fernández-Duval G, et al.
Metabolism. 2025 Sep;170:156195. doi: 10.1016/j.metabol.2025.156195. Epub 2025 Mar 17.
Metabolism. 2025.
PMID: 40107652
Free PMC article.
Clinical Trial.
In a long-term follow-up subsample (n = 1878) of the PREDIMED trial, among 337 candidate baseline plasma metabolites repeatedly assessed at baseline and after 1 year, 38 plasma metabolites were identified as predictors of all-cause mortality. ...The multi-metabolite signat …
In a long-term follow-up subsample (n = 1878) of the PREDIMED trial, among 337 candidate baseline plasma metabolites repeatedly asses …